KPRX Stock Forecast: Kiora Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.72
−12.28% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 60 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$3.2M
Ticker Nerd rank
60/ 100
Median analyst target
$7.00
Analysts covering
—
Revenue$0.0
Operating income−$2.1M
Net income−$2.1M
Free cash flow−$1.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−41.4%
1M
−69.1%
YTD
−63.4%
1Y
−60.0%
From 52W high
−74.8%
From 52W low
0.0%
$0.72
$2.86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Kiora Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
60/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
87
Revisions
67
Growth
66
Volatility
50
Quality
41
Issuance
36
Momentum
33
Value
14

Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (14): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

KPRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KPRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26KPRXHigh $7.00Median $7.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Sept 2025HC Wainwright & Co.ReiteratesBuy$10
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
12 Nov 2024HC Wainwright & Co.ReiteratesBuy—
22 Aug 2024HC Wainwright & Co.ReiteratesBuy—
23 July 2024HC Wainwright & Co.MaintainsBuy—
20 May 2024HC Wainwright & Co.ReiteratesBuy—
27 Mar 2024HC Wainwright & Co.MaintainsBuy—
9 Feb 2024HC Wainwright & Co.MaintainsBuy—
13 Nov 2023HC Wainwright & Co.ReiteratesBuy—
6 Nov 2023HC Wainwright & Co.MaintainsBuy—
24 Aug 2023HC Wainwright & Co.ReiteratesBuy—
14 Aug 2023HC Wainwright & Co.MaintainsBuy—
9 Aug 2023Maxim GroupMaintainsBuy—
12 May 2023HC Wainwright & Co.MaintainsBuy—
24 Mar 2023HC Wainwright & Co.ReiteratesBuy—
9 Feb 2023Maxim GroupUpgradeBuy—
8 Feb 2023HC Wainwright & Co.ReiteratesBuy—
8 Feb 2023Ladenburg ThalmannReiteratesBuy—
25 Aug 2022Ladenburg ThalmannInitiatesBuy$6.50
15 Aug 2022Maxim GroupDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

KPRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

KPRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Kiora Pharmaceuticals, Inc. returned −60.0% against +6.9% for the S&P 500, dividends included.

KPRX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26KPRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KPRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
3.2×

Cheaper than 34% of US stocks

Price / book
0.3×

Cheaper than 92% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−67.7%

Higher than 18% of US stocks

Return on assets
−21.3%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kiora Pharmaceuticals, Inc. has a market value of $3.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$11.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$8.6M.

  • Shares outstanding: 4.4M.

  • Kiora Pharmaceuticals, Inc. employs 13 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

KPRX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KPRXKiora Pharmaceuticals, Inc.$3.2M60
NRSNNeurosense Therapeutics Ltd.$3.2M3
APREAprea Therapeutics, Inc.$3.2M20
AZTRAzitra, Inc.$3.1M26
XBIOXenetic Biosciences, Inc.$3.3M28
SKYESkye Bioscience, Inc.$3.1M50
CELZCreative Medical Technology Holdings, Inc.$3.1M16

Take a look at KPRX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Kiora Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about KPRX

How does Ticker Nerd's model rank KPRX?

As at 21 Nov 2026, Kiora Pharmaceuticals, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).

What is the KPRX stock forecast for 2030?

No analyst covering Kiora Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KPRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $7 over the next 12 months.

How has KPRX stock performed over the past year?

Kiora Pharmaceuticals, Inc. returned -60.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kiora Pharmaceuticals, Inc. do?

Kiora Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other ophthalmic diseases. The company uses innovative small molecules to target pathways involved in vision loss, with programs designed to preserve, slow, or restore visual function.

Company

About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other ophthalmic diseases. The company uses innovative small molecules to target pathways involved in vision loss, with programs designed to preserve, slow, or restore visual function. Its pipeline includes therapies under development for inherited retinal disorders, inflammatory eye conditions, and corneal repair applications, reflecting a specialization in diseases with limited treatment options. Kiora Pharmaceuticals Inc. works at the intersection of eye health and drug development, addressing both rare and more broadly relevant ophthalmic indications through its research and clinical programs. Headquartered in Encinitas, California, the company plays a niche role in the healthcare sector by advancing experimental therapies aimed at unmet needs in vision care.

CEO Dr. Brian M. Strem Ph.D. · 13 employees · United States · https://www.kiorapharma.com